Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer - Miles, D.; de haas, S.; Dirix, L.; Romieu, G.; Chan, Arlene; Pivot, X.; Tomczak, P.; Provencher, L.; Cortes, J.; Delmar, P.; Scherer, S. (Nature Publishing Group, 2013)